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Abstract
Background: Adherence to guidelines is associated with improved outcomes of patients with acute coronary syndrome
(ACS). Clinical registries developed to assess quality of care at discharge often do not collect the reasons for non-
prescription for proven efficacious preventive medication in Continental Europe. In a prospective cohort of patients
hospitalized for an ACS, we aimed at measuring the rate of recommended treatment at discharge, using pre-specified
quality indicators recommended in cardiologic guidelines and including systematic collection of reasons for non-
prescription for preventive medications.
Methods: In a prospective cohort with 1260 patients hospitalized for ACS, we measured the rate of recommended
treatment at discharge in 4 academic centers in Switzerland. Performance measures for medication at discharge were pre-
specified according to guidelines, systematically collected for all patients and included in a centralized database.
Results: Six hundred and eighty eight patients(54.6%) were discharged with a main diagnosis of STEMI, 491(39%) of NSTEMI
and 81(6.4%) of unstable angina. Mean age was 64 years and 21.3% were women. 94.6% were prescribed angiotensin
converting enzyme inhibitors/angiotensin II receptor blockers at discharge when only considering raw prescription rates,
but increased to 99.5% when including reasons non-prescription. For statins, rates increased from 98% to 98.6% when
including reasons for non-prescription and for beta-blockers, from 82% to 93%. For aspirin, rates further increased from
99.4% to 100% and from to 99.8% to 100% for P2Y12 inhibitors.
Conclusions:We found a very high adherence to ACS guidelines for drug prescriptions at discharge when including reasons
for non-prescription to drug therapy. For beta-blockers, prescription rates were suboptimal, even after taking into account
reason for non-prescription. In an era of improving quality of care to achieve 100% prescription rates at discharge unless
contra-indicated, pre-specification of reasons for non-prescription for cardiovascular preventive medication permits to
identify remaining gaps in quality of care at discharge.
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Introduction
Cardiovascular disease remains the leading cause of death in
adults in the United States (US) and in Europe. Acute coronary
syndrome (ACS) is the most frequent cause leading to myocardial
infarction, heart failure, and sudden death [1]. In-hospital
initiation of evidence-based cardiovascular medication has been
shown to improve long-term drug adherence and clinical
outcomes [2,3,4].
Systematic monitoring of performance and annual report cards
on quality of care, such as the US Healthcare Effectiveness Data
and Information Set (HEDIS) [5], and financial incentives to
improve quality are not implemented in Switzerland. Current
clinical registries such as the NCDR ACTION Registry-GWTG
(National Cardiovascular Data Registry (NCDR) ACC’s Acute
Coronary Treatment and Intervention Outcomes (ACTION)
Registry- Get With the Guidelines (GWTG)) Network, a voluntary
participation registry of patients admitted with ACS in the USA,
the data collection to determine the rate of prescription of
recommended treatment at discharge includes a box to system-
atically measure if the treatment was contraindicated [6]. Current
clinical registries in Europe such as the FAST-MI registry [7,8], or
the APTOR registry [9], do not collect the reasons for non-
prescription. A recent report on quality at discharge in Switzerland
for patients discharged after a ST-elevation myocardial infarction
(STEMI) has shown an improvement in quality of care over the
last 15 years, but still suboptimal prescription rates of recom-
mended therapies at discharge [10,11,12]. However, given that
reasons for non-prescription were not collected, it is unknown if
differences are due to remaining gaps in quality of care of if they
are due to the absence of reporting on the reasons for non-
prescription.
We aimed at measuring the rate of recommended treatment at
discharge for patients hospitalized for an ACS in 4 university
hospitals in Switzerland, using pre-specified quality indicator
recommended in cardiologic guidelines in a centralized database,
and including systematic collection of reason for non-prescription
for preventive medication.
Methods
Study setting and participants
The SPUM-ACS (Special Program University Medicine-Acute
Coronary Syndromes) research network was established in 2008
and collects data since 2009 on a prospective cohort of patients
hospitalized for an ACS in 4 university medical centers in
Switzerland (University hospital of Bern (BE), Geneva (GE),
Lausanne (LA) and Zu¨rich (ZH)) [13,14]. We prospectively
included patients hospitalized from September 2009 to October
2010, aged .18 years, hospitalized within 72 hours after pain
onset with the main diagnosis of ACS. ACS was defined as patients
with symptoms comparable with angina pectoris (chest pain,
dyspnea) and at least one of the following characteristics: ST-
segment elevation or depression, T inversion or dynamic ECG
changes, evidence of positive Troponin and known coronary heart
disease (status after myocardial infarction, bypass surgery or
PTCA) [15]. The final ACS diagnosis was classified as follows:
STEMI (ST-segment elevation myocardial infarction or NSTEMI
non ST-segment elevation myocardial infarction or unstable
angina. Patients were included in the catheterization laboratory
in two participating hospitals (ZH and BE) and additionally while
on ward in two participating hospitals (LA and GE). In order to
allow comparison with other databases [6,16], we report on data
of patients who were discharged alive from each hospital.
Ethics statement
The study protocol was approved by the institutional review
board of all participating centers; namely, the Ethics Committee
on Clinical Research of the University of Lausanne, the Ethics
Committee of the Department for Internal Medicine and
Community Medicine of the University Hospital of Geneva, the
Cantonal Ethics Committee (KEK) of the Canton of Bern, and the
Cantonal Ethics Committee (KEK) of the Canton of Zurich. All
patients provided written, informed consent.
Data collection and endpoints
Clinical data for the patients included in the SPUM-ACS study
were collected by trained nurses and medical doctors on
standardized, web-based case report forms and stored in a central
database (Cardiobase, Clinical Trial Unit, and Department of
Cardiology, Bern University Hospital, Switzerland, and 2 mT,
Ulm, Germany). Data abstracted were (1) demographic charac-
teristics such as age, sex, race, education and (2) medical history,
such as previous coronary heart disease (CHD), stroke, renal
failure requiring dialysis, valvular heart disease, congestive heart
failure (CHF) as well as hypercholesterolemia, hypertension and
diabetes. We further collected administrative data of the hospital
stay (length of stay, direct transfer to a peripheral hospital or to
inpatient cardiac rehabilitation) and prescription of recommended
medication at discharge such as aspirin, P2Y12 inhibitors
(clopidogrel, prasugrel or ticagrelor), beta-blockers, angiotensin
converting enzyme inhibitors/angiotensin II receptor blockers
(ACEI/ATII) and statins.
Performance measures
Performance measures for medication at discharge were pre-
specified, systematically collected for all patients and included in
the centralized database. They were based on the ACC/AHA
2008 performance measures for adults with STEMI and NSTEMI
and included the following pre-specified reasons for non-prescrip-
tion [17]: for all medications, the reason ‘‘other reason
documented by physician’’ and ‘‘patient refusal’’ were included.
The reason in full text was entered when the reason ‘‘other reason
documented by physician‘‘ was selected. Additionally, pre-
specified reasons for aspirin were: ‘‘active bleeding during hospital
stay’’, ‘‘coumadin/warfarin prescribed at discharge’’ and ‘‘aspirin
allergy’’; for ACEI/ATII reasons were: ‘‘Moderate or severe aortic
stenosis’’ and ‘‘ACEI and/or ATII allergy’’; for beta-blockers,
reasons were: ‘‘beta-blocker allergy’’ and ‘‘second- or third-degree
atrio-ventricular heart block’’. We also included the reason
‘‘Bradycardia (heart rate ,60/min) on day of discharge’’ given
the frequency of this reported reason by physicians in some centers
and despite its absence of recognition an acceptable reason for
non-prescription in guidelines [17]. Patients who had ‘‘to be
introduced later’’ as the reason for non-prescription of beta-
blockers and who had been discharged home directly, were coded
as not having been prescribed the recommended medication. We
systematically collected information if patients had been offered a
specialized smoking cessation intervention in 2 university hospitals
(LA, GE). We did not collect information on brief smoking
cessation counseling interventions that may have taken place
during the hospital stay. In the US, smoking cessation counseling
was systematically monitored as part of a pay-for-performance
scheme rewarding hospitals for providing smoking cessation
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Table 1. Baseline characteristics of the participants to the study hospitalized for an acute coronary syndrome in 4 academic
centers in Switzerland from September 2009 to October 2010.
Overall N=1260 Unstable Angina N=81 NSTEMI N=491 STEMI N=688
Demographic variables
Age, y (mean 6 SD) 64612 67612 65613 62612
- ,50 years, N (col. %) 183 (14.5) 7 (8.6) 65 (13.4) 111 (16.3)
- 50 to ,65 years, N (col. %) 496 (39.4) 25 (30.9) 181 (36.9) 290 (42.0)
- 65 to 80 years, N (col. %) 438 (34.8) 36 (44.4) 177 (36.1) 225 (32.7)
- .80 years, N (col. %) 143 (11.4) 13 (16.1) 68 (13.9) 62 (9.0)
Female, N (%) 268 (21.3) 16 (19.8) 114 (23.2) 138 (20.1)
Race, N (%)
- Caucasian 1189 (94.6) 76 (93.8) 461 (94.4) 652 (94.8)
- Black 5 (.4) 0 (.0) 2 (.4) 3 (.4)
- Asian 7 (.6) 2 (2.5) 1 (.2) 4 (.6)
- Other 59 (4.7) 3 (3.7) 27 (5.5) 29 (4.2)
Education*
- Lower than apprenticeship, N (col. %) 230 (20.4) 21 (26.6) 103 (23.8) 106 (17.2)
- Apprenticeship or vocational school, N (col. %) 599 (53.6) 39 (49.4) 214 (49.5) 346 (56.9)
- High School or university graduation, N (col. %) 300 (26.6) 19 (24.1) 115 (26.6) 166 (26.8)
Clinical history
Previous hypercholesterolemia{, N (%) 742 (58.9) 62 (76.5) 327 (66.7) 353 (51.3)
Previous hypertension{, N (%) 742 (58.9) 62 (76.5) 327 (66.7) 353 (51.3)
Previous diabetes{, N (%) 227 (18.3) 16 (19.8) 109 (22.2) 102 (14.8)
Previous CHD, N (%) 276 (22.0) 51 (63.0) 135 (27.6) 90 (13.1)
- Previous PCI, N (%) 209 (16.6) 42 (51.9) 99 (20.3) 68 (9.9)
- Previous CABG, N (%) 74 (5.9) 15 (18.5) 37 (7.6) 22 (3.2)
Previous stroke, N (%) 36 (2.9) 3 (3.7) 16 (3.4) 17 (2.5)
Previous renal failure requiring dialysis, N (%) 8 (.7) 1 (1.2) 5 (1.1) 2 (.3)
Previous valvular heart disease, N (%) 32 (2.5) 1 (1.2) 23 (4.6) 8 (1.2)
Anthropomorphic variables
Obesity (BMI$30 kg/m2) 268 (21.6) 20 (25) 121 (24.9) 127 (18.8)
Behavioral variables
Current smoker, N (%) 480 (38.2) 23 (28.4) 170 (34.6) 287 (41.9)
Clinical variables
Left ventricular function, mean (6 SD) 51.5 (611.4) 55.7 (610.1) 54.7 (611.3) 48.9 (610.9)
- Left ventricular dysfunction (LVEF#40%), N (%) 220 (20.1) 6 (9.2) 58 (13.7) 156 (25.7)
Hospital stay
Coronary Revascularization
- Overall revascularization, N (%) 1170 (92.8) 56 (69.7) 439 (89.4) 675 (98.1)
* PCI, N (%) 1115 (88.4) 52 (64.2) 402 (81.9) 661 (96.1)
* CABG, N (%) 55 (4.4) 4 (4.9) 37 (7.5) 14 (2.0)
Destination at discharge, N (%)
- Home 541 (42.9) 62 (76.4) 231 (47.1) 248 (36.0)
- Direct transfer to inpatient cardiac rehabilitation 190 (15.1) 6 (7.4) 100 (20.4) 84 (12.2)
- Transfer to peripheral hospital 529 (42.0) 13 (16.1) 160 (32.6) 356 (51.7)
Length of stay, median (Q1,Q3), in days
- For patients directly discharged home 4.4 (2.3, 7) 2 (1, 5) 3.7 (1.9, 6.1) 5.5 (4.0, 7.2)
- For patients transferred to peripheral hospital 1 (.5, 1.5) 1 (.5, 1.5) 1 (.5, 1.5) 1 (.5, 1.5)
N, number of participants; BMI, body mass index; CABG, coronary artery by-pass graft; CHD, coronary heart disease; CR: cardiac rehabilitation; LVEF: Left ventricular
ejection fraction; CHF, congestive heart failure; NSTEMI: Non ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; Q1: first quartile; Q3;
third quartile; STEMI: ST-segment elevation myocardial infarction.
*38 participants with missing information on education status or who refused to disclose their education status.
{Previous hypercholesterolemia, hypertension and diabetes based on self-report by patients or previous treatment by preventive medication specific to the
hypercholesterolemia, hypertension or diabetes.
doi:10.1371/journal.pone.0093147.t001
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intervention. However, recent analyses in the US documented that
hospitals were able to ‘‘game the system,’’ with scores approaching
100% on the tobacco-treatment measure [18], prompting the
National Quality Forum to abandon tobacco-use intervention as a
quality measure [19].
Statistical analyses
Frequencies, means with standard deviations (SDs), medians
with interquartile ranges (IQR) were used when appropriate, as
were chi2 tests, Fisher’s exact test, Wilcoxon rank sum test and
ANOVA for bivariate analyses. Statistical significance was set at
0.05. All analyses were performed using STATA version 12
(StataCorp, College Station, Texas).
Results
Patients characteristics
A total of 1260 patients with a main diagnosis of ACS were
discharged from 4 university hospitals from September 2009 to
October 2010 (Table 1). 688 patients (54.6%) were discharged
with a main diagnosis of STEMI, 491 (39%) of NSTEMI and 81
(6.4%) of unstable angina. Mean age was 64 years and 21.3% were
women. 22% had had a previous CHD and 38.2% were current
smokers. Median length of stay for patients directly transferred
home was 5.5 days for patients with STEMI, 3.7 among
participants with NSTEMI and 2 among patients with unstable
angina. 541 (43%) were discharged home after the hospital stay,
190 (15%) were directly transferred to a stationary cardiac
rehabilitation facility and 529 (42%) to a peripheral hospital
(Table 1).
Prescription rates at discharge
For patients with a left ventricular ejection fraction (LVEF) of
#40%, the rate of patients hospitalized for ACS who were
prescribed ACEI/ATII at discharge was 94.6%. However, when
including reasons non-prescription, 99.6% were prescribed ACEI/
ATII or had a documented reason for non-prescription at
discharge. The rate of patients hospitalized for ACS who were
discharged on statins increased from 98% to 98.6% when
including reasons for non-prescription. For beta-blockers, rates
increased from 82% to 93% and for aspirin, from 99.4% to 100%.
For patients that had had a PCI-stent treatment, rates further
increase from 99.8% to 100% for P2Y12 inhibitor or had a
documented reason for non-prescription and 99.9% on dual
antiplatelet therapy (Table 2, Figure 1).147 patients discharged
home directly or to another facility had a documented reason for
non-prescription for beta-blockers, 8 for aspirin, 11 for ACEI/
ATII and 7 for statins (Table 3). The most commonly reported
reason for non-prescription for beta blockers was bradycardia
(n = 62), defined as a heart rate of,60 beats/minute on the day of
discharge. Sixty out of 1260 were discharged without the
recommended treatment and without any documented contra-
indication. Considering those discharged home directly, the type
of ACS was associated with lower rate of treatment at discharge. 7
(11%) participants with UA did not receive the recommended
treatment at discharge, 20(9%) with NSTEMI and 7(3%) with
STEMI (p =,0.001 for the comparison between STEMI and UA
or NSTEMI).
33% of smoking participants were offered a specialized smoking
cessation intervention in 2 university hospitals (GE, LA).
Discussion
We found high adherence to ACS guidelines for drug
prescriptions when including reasons for non-prescription to drug
therapy. For beta-blockers, prescription rates were suboptimal,
even after taking into account reason for non-prescription. In
addition, bradycardia was often reported as a reason for non-
prescription despite its absence from recommended reasons for
non-prescription in guidelines. The prescription rate of recom-
mended treatments were between 100% and 99% for antiplatelet
therapy, statin therapy and ACEI/ATII for patients with
LVEF#40% after taking into account pre-specified and docu-
mented reason for non-prescription, suggesting that the optimal
threshold has been achieved for these medications. Despite the
proven benefits of dedicated smoking cessation interventions, only
33% of smokers received such an intervention.
In countries with systematic performance monitoring such as
the US, an improvement of the recommended discharge
medication has been reported [20]. The NCDR ACTION
Registry-GWTG Network showed prescription rates for discharge
therapies according to percentiles of performance after exclusion
Figure 1. Percent of participants with recommended treatment at discharge taking into account reported reasons for non-
prescription. Abbreviations: P2Y12 inhibitors: clopidogrel, prasugrel or ticagrelor; ACEI/ATII : Angiotensin converting enzyme inhibitor/angiotensin
II receptor blockers. * P2Y12 inhibitors if PCI-stent treatment (n = 1066). ** ACEI/ATII inhibitors if left ventricular ejection fraction (LVEF) #40%
(n = 220).
doi:10.1371/journal.pone.0093147.g001
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of participants with reasons for non-prescription for each
medication. Hospitals in the top 10% of performance achieved
prescription rates of 99% for aspirin and beta-blockers, 86% for
P2Y12 inhibitors, 93% for ACEI/ATII and 94% for statins [6].
These results suggest that Swiss university hospitals would be
within the top 10% hospitals in the US for aspirin, P2Y12
inhibitors, ACEI/ATII and statins. For beta-blockers however, the
rate of prescription ranged below the top 10%, even after
including documented reasons for non-prescription. Various
quality improvement strategies have taken place in Switzerland
within the last decade at both regional and national level [21].
However, none of these quality improvement strategies included
financial incentives to improve quality of care or public reporting
of prescription rate at discharge. The improvement in quality of
care at discharge might be due to these quality improvement
strategies.
Comparative data on quality of care at discharge taking into
account reasons for non-prescription to medication is limited in
Switzerland. The only study which considered reasons for non-
prescription published so far was a retrospective chart review by
trained medical doctors which selected patients hospitalized for a
main diagnosis of acute myocardial infarction (AMI) (NSTEMI
and STEMI) in three out of the four academic medical centers
included in our study (BE, GE, LA) [16]. Patients transferred to
another hospital for inpatient care or who expired during the
hospital stay were excluded. Criteria for recommended medication
at discharge in 1999 were derived from the US Cooperative
Cardiovascular Project and adapted to the local context [16,22].
Statins at discharge and attendance to cardiac rehabilitation were
not abstracted. Patients in 1999 had similar baseline characteris-
tics, except a higher age (mean age 68.2 vs. 63.6), higher
proportion of women (35% vs. 18%) and previous CHD (36% vs.
22%). Comparing 2009–2010 data to the 1999 data, the
prescription rate of patients discharged at home after a NSTEMI
or STEMI increased from 91% in 1999 to 100% in 2009–2010 for
aspirin and from 81% to 94% for beta-blockers. In patients with a
left ventricular ejection fraction (LVEF) of less than 40%, the rates
increased from 79% to 100% for ACEI/ATII (p,0.001).
Data from a registry in Switzerland (AMIS Plus) on patients
with STEMI suggested that 84.2% were discharged on a P2Y12
inhibitor, 96% on aspirin, 89% on an ACEI/ATII, 91.7% on
statins and 79.2% on beta-blockers in 2011, but report on quality
data was on a voluntary basis and reasons for non-prescription
were not reported [10,11]. Quality at discharge for patients with
STEMI has been reported in France showing high prescription
rates of evidence based medication [8]. 95% were discharged on
aspirin, 84% on beta-blockers and 75% on ACEI. However,
reason for non-prescription to prescription medication was not
reported. In an era of targets of prescription rates close to 100%
unless contra-indicated, pre-specification of the reasons for
Table 2. Documented Treatment at Discharge for participants hospitalized for an acute coronary syndrome in 4 academic centers
Switzerland from Sept 2009 to October 2010.
Overall N=1,260 Unstable angina N=81 NSTEMI N=491 STEMI N=688
Aspirin, % including reasons for not
prescribing (NP)
100% 100% 100% 100%
- % prescribed regardless of reasons for NP 99.4% 98.8% 99% 99.7%
- Reason for NP documented, N/N eligible 8/1260 1/81 5/491 2/688
P2Y12 inhibitors if PCI-stent treatment, %
including reasons for NP
99.9% 100% 99.7% 100%
- % prescribed regardless of reasons for NP 99.8% 100% 99.5% 100%
- Reason for NP documented, N/N eligible 1/1066 0/47 1/379 0/640
Dual antiplatelet therapy (DAPT) if PCI-stent
treatment, % including reasons for NP
99.9% 100% 99.7% 100%
Beta-blockers, % including reasons for NP 93.3% 87.7% 90.4% 95.9%
- % prescribed regardless of reasons for NP 81.7% 76.5% 83.3% 81.1%
- Reason for NP documented, N/N eligible 147/1260 11/81 45/491 91/688
AT II antagonist/ACE inhibitors (LVEF#40%),
% including reasons for NP
99.5% 83.3% 100% 100%
- % prescribed regardless of reasons for NP 94.6% 83.3% 87.9% 97.4%
- Reason for NP documented, N/N eligible 11/220 0/6 7/58 4/156
Statins, % including reasons for NP 98.6% 96.3% 98.0% 99.3%
- % prescribed regardless of reasons for NP 98.0% 95.1% 97.4% 98.8%
- Reason for NP documented, N/N eligible 7/1260 1/81 3/491 3/688
Concomitant documentation of Aspirin,
Statin, Beta-blockers and AT II
antagonist/ACE inhibitors, %*
95.2% 88.9% 94.3% 96.7%
Nitrate documentation, % 6.9% 18.5% 9.6% 3.6%
DAPT: Dual antiplatelet therapy; N, number of participants; STEMI: ST-segment elevation myocardial infarction; NP: non-prescription; NSTEMI: Non ST-segment elevation
myocardial infarction; LVEF, left ventricular ejection fraction.
* Concomitant prescription at discharge unless contra-indicated or not indicated for aspirin, clopidogrel/prasugrel or ticagrelor if PCI-stent treatment, beta-blocker,
statin, ACEI if EF#40%. When participants transferred to peripheral hospital, beta-blocker and ACEI/ATII coded as not applicable.
Prescription rates according to guidelines taking into account reported indications reasons for not prescribing medication at discharge.
doi:10.1371/journal.pone.0093147.t002
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non-prescription within the data collection forms permits to
identify the remaining gaps in quality at discharge. The 100%
prescription rates observed for aspirin and P2Y12 inhibitor
obviously suggest that no further increase in quality can be
achieved for the prescription rates of these medications, however,
it permitted us to identify that beta-blockers might still be
underutilized and that reasons for non-prescription such as
bradycardia, which is not recognized as a contra-indication by
current guidelines needs to be improved.
ESC and AHA Guidelines recommend the adoption of
dedicated smoking cessation program in each hospital [23,24].
Only 33% of smokers received dedicated smoking cessation
interventions during the hospital stay. The beneficial effect of a
systematic high intensity smoking cessation intervention to all
smokers is currently assessed in the participating hospitals.
Potential limitations
These data are derived from university hospitals and might not
represent patients hospitalized for an ACS in other hospital in
Table 3. Documented reasons for not prescribing recommended cardiovascular medication at discharge.
Documented reasons for not prescribing
medication in patients discharged home, in
cardiac rehabilitation or to another facility
Documented reasons for not
prescribing medication in patients
discharged home directly
Aspirin 8 3
- Active bleeding during hospital stay 0 0
- Coumadin/warfarin prescribed at discharge 5 2
- Aspirin allergy 3 1
- Other reason documented by physician for not prescribing 0 0
- Patient refusal 0 0
- Introduced later (in peripheral hospital) 0 NA
- Other reason 0 0
Beta-blocker (only patients not transferred in peripheral
hospital considered)
147 41
- Beta-blocker allergy 2 2
- Second- or third-degree atrio-ventricular heart block 8 4
- Bradycardia (heart rate ,60/min) on day of discharge 62 25
- Hypotension 10 3
- Asthma or COPD 1 1
- Other reason documented by physician for not prescribing 17 6
- Patient refusal 0 0
- Introduced later (in peripheral hospital) 47 NA{
- Other reason 0 0
ACEI/ATII (only patients not transferred in peripheral
hospital and with LVEF#40% considered)
11 1
- Moderate or severe aortic stenosis 0 0
- ACEI or ATII allergy 1 0
- Other reason documented by physician for not prescribing 1 0
- Renal failure 4 1
- Hypotension 1 0
- Patient refusal 0 0
- Introduced later (in peripheral hospital) 4 NA
- Other reason 0 0
Statins 7 2
- Statin medication allergy 0 0
- Reason documented by physician for not prescribing 3 0
- Statin intolerance 3 2
- Patient refusal 0 0
- Introduced later (in peripheral hospital) 1 NA
- Other reason 0 0
ACEI: Angiotensin Converting Enzyme Inhibitor; ATII: Angiotensin II receptor blockers; NA: Not applicable; NR: not reported.
{6 patients discharged home directly and who had ‘‘to be introduced later’’ as the reason for not prescription were coded as not having been prescribed the
recommended medication.
doi:10.1371/journal.pone.0093147.t003
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Switzerland. Compared to the AMIS+, a national registry in
academic and non-academic centers accounting for 78 out of 106
hospitals treating ACS in Switzerland, the mean age of partici-
pants with STEMI was similar in both men and women, but was
lower than in other registries in Europe, and rates of revascular-
ization were higher [11,25,26]. These differences in mean age and
rate of catheterization might be due to the fact that patients were
essentially included in the catheterization laboratory in two
participating hospitals. Those patients undergoing catheterization
are known to be younger than the total number of patients with
ACS [27]. Elderly ACS patients and those not undergoing
catheterization have been shown to be less likely to receive
evidence-based therapies [27,28]. In these patients, who may have
more comorbidities, the adherence to guidelines could be still
suboptimal even including the reasons for not prescription. We
urge for careful comparison of the reported rates of treatment
according to guidelines at discharge in our studied sample with
other registries. The aim of this study was not to report on the
quality of care for all patients in Switzerland, but to determine the
importance of collecting reasons for non-prescription in databases
to detect remaining gaps in quality of care in a sample of
participants with high rate of recommended treatment at
discharge. We found an association between the type of ACS
and prescription of recommended treatment, including reasons for
non-prescription. These results should be carefully interpreted due
to the low number of participants without recommended
treatment at discharge. Rates of referral to stationary cardiac
rehabilitation were based on information at discharge. In
Switzerland, both stationary cardiac rehabilitation and ambulato-
ry cardiac rehabilitation are available. The reported rate of direct
transfer to and stationary cardiac rehabilitation facility from the
hospital does not reflect the overall attendance rate to cardiac
rehabilitation in Switzerland. Future analyses should explore the
attendance rate to cardiac rehabilitation using data at discharge
and follow-up.
Conclusions
We found a found high adherence to ACS guidelines for drug
prescriptions when including reasons for non-prescription to drug
therapy. Achieved rates of prescribed medication at discharge
were above 99% for Aspirin, P2Y12 inhibitors, ACEI/ATII and
statins. Prescription rates for beta-blockers taking into account
reasons for non-prescription were lower at 94%. In an era of
improving quality of care to achieve 100% prescription rates at
discharge unless contra-indicated, pre-specification of reasons for
non-prescription for cardiovascular preventive medication within
clinical registries permits to identify remaining gaps in quality of
care at discharge.
Author Contributions
Conceived and designed the experiments: RA BG NR. Performed the
experiments: RA BG LR RK SC DC DN JC PV PJ CMM SW TFL FM
NR. Analyzed the data: RA BG NR. Contributed reagents/materials/
analysis tools: JC PV JPV CMM SW TFL FM NR. Wrote the paper: RA
BG NR. Critical revision of the manuscript: RA BG LR RK SC DC DN
JC JPV PV PJ CMM SW TFL FM NR. Interpretation of data: RA BG LR
DN JPV CMM SW NR.
References
1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, et al. (2012) Heart
disease and stroke statistics–2012 update: a report from the American Heart
Association. Circulation 125: e2–e220.
2. Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, et al. (2002) Outpatient
adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll
Cardiol 40: 1589–1595.
3. Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, et al. (2005) Early
initiation of lipid-lowering therapy for acute coronary syndromes improves
compliance with guideline recommendations: observations from the Orbofiban
in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am
Heart J 149: 444–450.
4. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, et al. (2008)
Improvements in long-term mortality after myocardial infarction and increased
use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll
Cardiol 51: 1247–1254.
5. HEDIS Health Plan Employer Data and Information Set. Washington, DC:
National Committee for Quality Insurance (NCQA) website Available: http://
www.ncqa.org/. Accessed 2014 March 6.
6. Peterson ED, Roe MT, Chen AY, Fonarow GC, Lytle BL, et al. (2010) The
NCDR ACTION Registry-GWTG: transforming contemporary acute myocar-
dial infarction clinical care. Heart 96: 1798–1802.
7. Ferrieres J, Bataille V, Leclercq F, Geslin P, Ruidavets JB, et al. (2009) Patterns
of statin prescription in acute myocardial infarction: the French registry of Acute
ST-elevation or non-ST-elevation Myocardial Infarction (FAST-MI). Athero-
sclerosis 204: 491–496.
8. Belle L, Labarere J, Fourny M, Drouet E, Mulak G, et al. (2012) Quality of care
for myocardial infarction at academic and nonacademic hospitals. Am J Med
125: 365–373.
9. Zeymer U, James S, Berkenboom G, Mohacsi A, Iniguez A, et al. (2012)
Differences in the use of guideline-recommended therapies among 14 European
countries in patients with acute coronary syndromes undergoing PCI. Eur J Prev
Cardiol.
10. Radovanovic D, Urban P, Simon R, Schmidli M, Maggiorini M, et al. (2010)
Outcome of patients with acute coronary syndrome in hospitals of different sizes.
A report from the AMIS Plus Registry. Swiss Med Wkly 140: 314–322.
11. Radovanovic D, Nallamothu BK, Seifert B, Bertel O, Eberli F, et al. (2012)
Temporal trends in treatment of ST-elevation myocardial infarction among men
and women in Switzerland between 1997 and 2011. European Heart Journal:
Acute Cardiovascular Care.
12. Wieser S, Ra Themann I, De B, Eichler K, Pletscher M, et al. (2012) Cost of
acute coronary syndrome in Switzerland in 2008. Swiss Med Wkly 142: 0.
13. Matter CM, Klingenberg R, Templin C, Altwegg L, Ra¨ber L, et al. (2010)
Inflammation and acute coronary syndromes (ACS) – a clinical research network
funded by the Swiss National Science Foundation. Kardiovaskula¨re Medizin 13:
31–34.
14. Carballo D, Auer R, Carballo S, Windecker S, Matter C, et al. (2010) [A Swiss
multicentric project to improve the prevention of cardiovascular event
recurrence after acute coronary syndromes]. Rev Med Suisse 6: 518–524.
15. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, et al. (2007) Universal
definition of myocardial infarction. Circulation 116: 2634–2653.
16. Luthi JC, McClellan WM, Flanders WD, Pitts SR, Burnand B (2005) Variations
in the quality of care of patients with acute myocardial infarction among Swiss
university hospitals. Int J Qual Health Care 17: 229–234.
17. Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, et al. (2008)
ACC/AHA 2008 performance measures for adults with ST-elevation and non-
ST-elevation myocardial infarction: a report of the American College of
Cardiology/American Heart Association Task Force on Performance Measures
(Writing Committee to develop performance measures for ST-elevation and
non-ST-elevation myocardial infarction): developed in collaboration with the
American Academy of Family Physicians and the American College of
Emergency Physicians: endorsed by the American Association of Cardiovascular
and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and
Interventions, and Society of Hospital Medicine. Circulation 118: 2596–2648.
18. Levy DE, Kang R, Vogeli CS, Rigotti NA (2011) Smoking cessation advice rates
in US hospitals. Arch Intern Med 171: 1682–1684.
19. Fiore MC, Goplerud E, Schroeder SA (2012) The Joint Commission’s New
Tobacco-Cessation Measures — Will Hospitals Do the Right Thing? New
England Journal of Medicine 366: 1172–1174.
20. Jernberg T, Johanson P, Held C, Svennblad B, Lindba¨ck J, et al. (2011)
Association Between Adoption of Evidence-Based Treatment and Survival for
Patients With ST-Elevation Myocardial Infarction. JAMA: The Journal of the
American Medical Association 305: 1677–1684.
21. Luthi JC, McClellan WM, Flanders WD, Pitts S, Burnand B (2002) Quality of
health care surveillance systems: review and implementation in the Swiss setting.
Swiss Med Wkly 132: 461–469.
22. Marciniak TA, Ellerbeck EF, Radford MJ, Kresowik TF, Gold JA, et al. (1998)
Improving the Quality of Care for Medicare Patients With Acute Myocardial
Infarction: Results From the Cooperative Cardiovascular Project. JAMA 279:
1351–1357.
23. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, et al. (2011) ESC
Guidelines for the management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation: The Task Force for the
management of acute coronary syndromes (ACS) in patients presenting without
Quality of Care after Acute Coronary Syndromes
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e93147
persistent ST-segment elevation of the European Society of Cardiology (ESC).
Eur Heart J 32: 2999–3054.
24. Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, et al. (2012) ESC
Guidelines for the management of acute myocardial infarction in patients
presenting with ST-segment elevation: The Task Force on the management of
ST-segment elevation acute myocardial infarction of the European Society of
Cardiology (ESC). Eur Heart J 33: 2569–2619.
25. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, et al. (2011) Recent
trends in the incidence, treatment, and outcomes of patients with STEMI and
NSTEMI. Am J Med 124: 40–47.
26. Bajaj RR, Goodman SG, Yan RT, Bagnall AJ, Gyenes G, et al. (2013)
Treatment and outcomes of patients with suspected acute coronary syndromes
in relation to initial diagnostic impressions (insights from the Canadian Global
Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute
Coronary Events [CANRACE]). Am J Cardiol 111: 202–207.
27. Alexander KP, Newby LK, Bhapkar MV, White HD, Hochman JS, et al. (2006)
International variation in invasive care of the elderly with acute coronary
syndromes. Eur Heart J 27: 1558–1564.
28. Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, et al. (2005) Impact of
age on management and outcome of acute coronary syndrome: observations
from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 149:
67–73.
Quality of Care after Acute Coronary Syndromes
PLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e93147
